SGLT2 Inhibitors Market Size, Share, Trends & Forecast
The sglt2 inhibitors Market is expanding as healthcare systems respond to the rising prevalence of diabetes and related chronic conditions. According to WiseGuyReports, the market was valued at USD 4.96 billion in 2024 and USD 5.49 billion in 2025, with revenue projected to reach USD 15.0 billion by 2035 at a CAGR of 10.6% during 2026–2035.
Type 2 diabetes remains the dominant application segment. The report values this segment at approximately USD 3 billion in 2024 and projects it to reach USD 8 billion by 2035. Growing diabetes prevalence, increasing awareness of treatment options, and demand for effective long-term disease management are supporting market expansion.
The therapeutic scope of SGLT2 inhibitors is also expanding beyond diabetes management. Heart failure and chronic kidney disease are increasingly important application areas, creating additional opportunities for pharmaceutical companies as clinical understanding of these medicines develops.
Oral formulations currently represent the stronger route-of-administration segment because of their convenience and ease of use. Injectable products remain a smaller category but may serve particular patient requirements. The growing preference for convenient treatment formats is encouraging manufacturers to continue investing in oral drug development.
North America is expected to maintain market leadership, while Asia-Pacific is forecast to record faster growth as diabetic populations increase and healthcare infrastructure improves. Expansion into emerging markets is therefore becoming an important opportunity for SGLT2 inhibitor manufacturers.